Published in Cancer Weekly, March 8th, 2005
"The acute and cumulative dose-related toxicity and drug resistance, mediated via nuclear factor kappa B (NFkappaB), of anthracycline anticancer drugs pose a major problem in cancer chemotherapy," according to scientists in the United States.
"Here, we report that oral silibinin (a flavanone) suppresses human non-small-cell lung carcinoma A549 xenograft growth (p=0.003) and enhances the therapeutic response (p<0.05) of doxorubicin in athymic BALB/c nu/nu mice together with a strong prevention of doxorubicin-caused adverse health effects," wrote R.P. Singh and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.